Vaxart, Inc.

VXRT ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $16.3M $-66.9M $-82.5M $-107.8M $-70.5M $-32.2M $-18.6M $-18.0M
Depreciation & Amortization $8.6M $8.9M $8.6M $5.8M $4.2M $2.7M $3.6M $3.2M
Depreciation $3.5M $3.7M $3.8M $2.0M $732.0K $114.0K $504.0K $476.0K
Amortization $700.0K $700.0K $700.0K $1.3M $1.7M $1.7M $2.3M $2.7M
Stock-Based Compensation $8.3M $11.5M $14.1M $13.6M $8.9M $4.4M $627.0K $539.0K
Net Cash from Operating Activities $7.7M $-44.8M $-70.5M $-94.8M $-59.8M $-23.8M $-13.1M $-14.5M
Investing Activities
Capital Expenditures $145.0K $554.0K $1.9M $9.6M $5.2M $1.2M $850.0K $707.0K
Business Acquisitions $0 $4.8M $21.0K
Net Cash from Investing Activities $16.6M $-21.3M $44.0M $-20.4M $-49.1M $-1.2M $-850.0K $26.2M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $4.2M $56.6M $15.2M $17.5M $125.8M $138.3M $16.0M $-1.7M
Net Change in Cash $28.6M $-9.5M $-11.3M $-97.7M $16.9M $113.3M $2.0M $9.9M
Free Cash Flow $7.6M $-45.3M $-72.3M $-104.4M $-65.0M $-25.0M $-13.9M $-15.3M
← Newer Page 1 of 3 Older →
Benjamin Graham

Those who do not remember the past are condemned to repeat it.